Home Cart Sign in  
Chemical Structure| 124387-19-5 Chemical Structure| 124387-19-5

Structure of 5(6)-CFDA
CAS No.: 124387-19-5

Chemical Structure| 124387-19-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

5(6)-CFDA is a cell-permeant esterase substrate that can serve as a viability probe that measures both enzymatic activity, which is require to activate its fluorescence, and cell-membrane integrity, which is required for intracellular retention of their fluorescent product.

Synonyms: 5-(6)-Carboxyfluorescein diacetate; CFDA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 5(6)-CFDA

CAS No. :124387-19-5
Formula : C25H16O9
M.W : 460.39
SMILES Code : O=C1OC2(C3=C1C=CC(C(O)=O)=C3)C4=C(C=C(C=C4)OC(C)=O)OC5=C2C=CC(OC(C)=O)=C5.O=C6OC7(C8=C(OC9=C7C=CC(OC(C)=O)=C9)C=C(OC(C)=O)C=C8)C%10=C6C=C(C(O)=O)C=C%10
Synonyms :
5-(6)-Carboxyfluorescein diacetate; CFDA
MDL No. :MFCD00467494

Safety of 5(6)-CFDA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03449459 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Early Phase 1 Not yet recruiting December 2020 China, Guangdong ... More >> The First Affiliated Hospital of Guangzhou Medical University Not yet recruiting Guangzhou, Guangdong, China Contact: Bing Yuan, PhD    020-83205181    506638016@qq.com    China, Shanghai Ruijin Hospital, Shanghai Jiao Tong University Not yet recruiting Shanghai, Shanghai, China Contact: Ranran Dai, Master    021-34186000    drrcyy@msn.com    Shanghai Zhongshan Hospital Not yet recruiting Shanghai, Shanghai, China Contact: Jing Zhang, MD,PhD    021-64041990    huxizhangjing@foxmail.com    Contact: Jing Bi, Master    021-64041990    bi.jing@zs-hospital.sh.cn Less <<
NCT03621072 Bioequivalence Phase 1 Not yet recruiting May 2019 -
NCT03157726 Benign Prostatic Hyperplasia Not Applicable Recruiting June 1, 2021 China, Guangdong ... More >> Zhujiang Hospital of Southern Medical University Recruiting Guangzhou, Guangdong, China, 510282 Contact: Shaobo SB Zheng, M.D    +86-13602888356    1h1h1h864@sina.com    Contact: ChunXiao CX Liu, M.D., Ph.D    +86-13302296795    liuchx888@hotmail.com Less <<
NCT02991872 Virus Diseases Phase 4 Completed - China ... More >> GSK Investigational Site Mengshan, China, 546700 Less <<
NCT02810522 Blood Glucose Measurement Not Applicable Unknown March 2017 -
NCT03282266 Pulmonary Arterial Hypertensio... More >>n Less << Not Applicable Recruiting July 30, 2021 China, Jiangsu ... More >> Nanjing First Hospital Recruiting Nanjing, Jiangsu, China, 210006 Contact: Shaoliang Chen, MD    +86 13605157029    chmengx@126.com    Contact: Hang zhang, MD    +86 13951922158    dxh_nari@sina.com Less <<
NCT00856401 Hypoparathyroidism Phase 3 Active, not recruiting June 30, 2021 United States, New York ... More >> Columbia University Medical Center New York, New York, United States, 10032 Less <<
NCT03353480 Bioequivalence Phase 1 Completed - China, Jilin ... More >> The First Hospital of Jilin University/Phase I Clinical Trials Unit Changchun, Jilin, China, 130021 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.86mL

2.17mL

1.09mL

21.72mL

4.34mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records